Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms

Pituitary neuroendocrine tumors (PitNET) are commonly benign tumors accounting for 10-25% of intracranial tumors. Prolactin-secreting adenomas represent the most predominant type of all PitNET and for this subtype of tumors, the medical therapy relies on the use of dopamine agonists (DAs). DAs yield...

Descripción completa

Detalles Bibliográficos
Autores principales: Pivonello, Claudia, Patalano, Roberta, Negri, Mariarosaria, Pirchio, Rosa, Colao, Annamaria, Pivonello, Rosario, Auriemma, Renata Simona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789681/
https://www.ncbi.nlm.nih.gov/pubmed/35095761
http://dx.doi.org/10.3389/fendo.2021.791633

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789681/
https://www.ncbi.nlm.nih.gov/pubmed/35095761
http://dx.doi.org/10.3389/fendo.2021.791633

Ejemplares similares